Lisata Therapeutics (NASDAQ:LSTA – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $15.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 431.12% from the stock’s previous close. […]